Saitama Medical Univ. Develops Jointly with Daiichi Sankyo New Antibody with Potential Application in Treatment of FOP

Saitama Medical University announced on October 25 that the university’s research team has developed, through collaboration with Daiichi Sankyo, an antibody that inhibits the transmembrane receptor (ALK2) that causes an activating mutation in fibrodysplasia ossificans progressiva (FOP). Researchers in the...read more